SAN DIEGO, May 23, 2016 /PRNewswire/ -- GenomeDx Biosciences today announced that four presentations featuring Decipher Genomics Resource Information Database (Decipher GRID®) and Decipher® Tests in Prostate Cancer will be presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting held June 3-7 in Chicago.
The abstract titled "Development and Validation of Genomic Signature that Predicts ADT Treatment Failure," was chosen to be discussed at the Poster Discussion Session, and will be presented by R. Jeffrey Karnes, M.D., associate professor and vice chair in urology at Mayo Clinic, on Saturday, June 4 from 4:45 p.m. to 6:00 p.m. CDT.
Poster Discussion:
Title: Development and Validation of Genomic Signature that Predicts ADT Treatment Failure
Date: Saturday, June 4, 2016
Poster Session: Hall A (1:00 p.m. to 4:30 p.m. CDT)
Discussion Session: Hall D1 (4:45 p.m. to 6:00 p.m. CDT)
Abstract Number: 5018
Poster Number: 275
Presenter: R. Jeffrey Karnes, M.D., Mayo Clinic
Poster Presentations:
Title: Effect of a Genomic Classifier on Adjuvant Treatment Decision-Making Among Patients with High-Risk Pathology at Radical Prostatectomy: Results from the Multicenter Prospective PRO-IMPACT Study
Date: Saturday, June 4, 2016
Poster Session: Hall A (1:00 p.m. to 4:30 p.m. CDT)
Abstract Number: e16558
Poster Number: 310
Presenter: John L. Gore, M.D., M.S., University of Washington School of Medicine
Title: Deciphering the Genomic Fingerprint of Small Cell Prostate Cancer with Potential Clinical Utility in Radical Prostatectomy Tissues
Date: Saturday, June 4, 2016
Poster Session: Hall A (1:00 p.m. to 4:30 p.m. CDT)
Abstract Number: 5055
Poster Number: 312
Presenter: Elai Davicioni, Ph.D., GenomeDx Biosciences
Title: Validation of a Genomic Risk Classifier to Predict Prostate Cancer-Specific Mortality (PCSM) in High-Risk Patients
Date: Saturday, June 4, 2016
Poster Session: Hall A (1:00 p.m. to 4:30 p.m. CDT)
Abstract Number: 5056
Poster Number: 313
Presenter: R. Jeffrey Karnes, M.D., Mayo Clinic
About Decipher® Prostate Cancer Classifier Tests
Our Decipher prostate cancer classifier tests are currently comprised of Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient's unique genomic profile. Decipher Biopsy is indicated for men after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.
Learn more at www.DecipherTest.com
About Decipher GRID®
Our Decipher Genomics Resource Information Database (Decipher GRID) is a genomic expression database that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patient tumors, and constitutes what we believe to be the world's largest shared, clinically-annotated genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables us to more rapidly discover, develop, commercialize and drive the adoption of our existing and new genomic tests. Through Decipher GRID, GenomeDx is building a suite of genomic tests in urologic cancer that we believe will allow us to achieve our goals of reducing costs to the healthcare system and improving patient lives, from screening through late-stage therapy.
Learn more at www.DecipherGRID.com
About GenomeDx Biosciences
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and has offices in San Diego, California.
Learn more at www.GenomeDx.com
SOURCE GenomeDx Biosciences Inc.